Clinical Trial Update: Study of the GARFT Inhibitor AG2037 in Patients With Metastatic Colorectal Cancer Who Failed Treatment [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating AG2037, a GARFT inhibitor, in metastatic colorectal cancer patients who failed prior treatment has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• AG2037 (GARFT inhibitor AG2037)

Snippet

Sponsor: Pfizer | Conditions: Colorectal Neoplasms | Phase 2 | Status: COMPLETED